Evaluate and manage disorders of sex development and the neonate with ambiguous genitalia

In one line

A disorder of sex development (DSD) is a congenital mismatch between chromosomal, gonadal and phenotypic sex; the neonate with ambiguous genitalia is a social and a medical emergency at once, and the two consultant duties that override everything else are to find and treat salt-wasting congenital adrenal hyperplasia before it kills the baby and to resist assigning a sex, naming, or operating until a multidisciplinary work-up is complete.

The assessment of the ambiguous newborn is built up from first principles at ambiguous genitalia basics; that groundwork — the bedside examination, the parental conversation, the initial panic-management — is assumed here. The focus is the consultant layer: classifying the underlying condition correctly, stratifying the danger, and holding a defensible line through the genuinely contested decisions about surgery, gonadectomy and sex of rearing.

Mechanism & pathophysiology

Sex development runs as a sequence — chromosomal sex sets gonadal sex, gonadal sex sets hormonal output, and hormones build the ducts and the external genitalia — and a DSD is a lesion somewhere along that chain. Reading the chain backwards from the phenotype to the lesion is the whole diagnostic exercise.

Gonadal determination. The bipotential gonad is identical in both sexes until about six weeks. SRY on the short arm of the Y chromosome is the master switch: it upregulates SOX9, which drives the supporting cells down the Sertoli (testis) pathway. Without a functioning SRY/SOX9 cascade — and with the pro-ovarian signals WNT4/RSPO1 and FOXL2 unopposed — the gonad becomes an ovary. The cascade is dose- and timing-sensitive: a mutation in SRY, SOX9, NR5A1 (SF1), WT1, MAP3K1 or the dosage-sensitive NR0B1 (DAX1) locus can produce a 46,XY individual with dysgenetic or frankly ovarian gonads, and translocation of SRY onto an X can produce a 46,XX testicular DSD.

Duct and external-genital differentiation are hormone-driven, and the two hormones act independently. Once a testis forms, Sertoli cells secrete anti-Müllerian hormone (AMH), which regresses the Müllerian ducts (otherwise the uterus, tubes and upper vagina). Leydig cells secrete testosterone, which stabilises the Wolffian ducts into epididymis, vas and seminal vesicles. The external genitalia are a separate matter again: they masculinise only under dihydrotestosterone (DHT), the 5α-reductase product of testosterone, acting through the androgen receptor. This separation is the key to several conditions. A 46,XY fetus with 5α-reductase type 2 deficiency makes testosterone (so the internal Wolffian structures form and AMH regresses the uterus) but cannot make DHT, so the external genitalia are undervirilised at birth and then virilise at puberty under the testosterone surge — the classic "born a girl, becomes a boy" history. A 46,XY fetus with complete androgen insensitivity (CAIS) makes testosterone and AMH normally but cannot respond to either androgen: no uterus (AMH worked), no Wolffian structures, female external genitalia, a blind-ending vagina and intra-abdominal testes — phenotypically female, 46,XY, presenting later with primary amenorrhoea or inguinal "hernias" that are testes.

The 2006 Chicago consensus classification is the framework every answer is organised around. It abandoned the stigmatising "intersex/pseudohermaphrodite" language for three karyotype-anchored groups:

• 46,XX DSD — the gonad is an ovary, the karyotype is XX, and the genitalia are virilised. The overwhelmingly commonest cause, and the one that can kill, is congenital adrenal hyperplasia (CAH), almost always 21-hydroxylase deficiency: the adrenal cannot make cortisol (and, in the salt-wasting form, aldosterone), ACTH drives adrenal hyperplasia, and the blocked precursors are shunted into the androgen pathway, virilising a genetically female fetus in utero. Rarer 46,XX causes include aromatase deficiency and maternal androgen exposure (luteoma, exogenous androgens).
• 46,XY DSD — a Y chromosome and a testis (or dysgenetic gonad) but undervirilised genitalia. Causes split into disorders of androgen action/synthesis (CAIS and partial AIS, 5α-reductase deficiency, testosterone-biosynthesis defects) and disorders of gonadal development (complete or partial gonadal dysgenesis, e.g. Swyer syndrome — a 46,XY phenotypic female with streak gonads and a uterus, because dysgenetic gonads make neither AMH nor testosterone).
• Sex-chromosome DSD — the abnormality is in the chromosome complement itself: 45,X (Turner syndrome), 47,XXY (Klinefelter syndrome), 45,X/46,XY mixed gonadal dysgenesis (asymmetric gonads — a testis on one side, a streak on the other, often a uterus, frequently ambiguous genitalia and a high tumour risk), and ovotesticular DSD (both ovarian and testicular tissue in the same individual, in one gonad as an ovotestis or in opposite gonads — the modern term for the old "true hermaphroditism", commonly 46,XX in African series).

Holding this classification is not an academic exercise: it tells you which neonate is at risk of an adrenal crisis (46,XX CAH), which has a cancer-prone intra-abdominal gonad (dysgenetic or Y-bearing), and which will declare a gender trajectory that may diverge from the natal genital appearance.

The mechanistic detail that earns the diagnosis is the discordance between the three layers — Müllerian structures, Wolffian structures, and the external phenotype — because each is driven by a different signal and so points to a different lesion. A uterus that is present means AMH was either never made (no functioning Sertoli tissue: a 46,XX, or a dysgenetic 46,XY gonad) or was made but not the relevant problem; a uterus that is absent in a 46,XY individual confirms AMH worked, so the lesion is downstream in androgen synthesis or action (AIS, 5α-reductase deficiency, a testosterone-synthesis block). Virilised external genitalia in a 46,XX infant with a normal uterus and ovaries localises the androgen source to the adrenal (CAH) or, rarely, a maternal/placental source — not to the gonad. This three-layer logic, applied to the ultrasound and the steroid profile, is what converts a karyotype plus a hormone panel into a specific diagnosis rather than a list of possibilities.

Assessment

A newborn whose genitalia cannot be confidently called male or female is never assigned a sex on the labour ward, given a gendered name, or sent home before the work-up runs. The two parallel imperatives — exclude life-threatening salt-wasting CAH, and establish the underlying diagnosis without prejudging the answer — drive everything.

The features that make genitalia genuinely ambiguous (and mandate the full pathway, not reassurance): an apparent male with non-palpable testes, hypospadias with a bifid scrotum, or a stretched phallus length below the normal range; an apparent female with clitoromegaly, posterior labial fusion or a palpable gonad in the labioscrotal fold or groin; any discordance between an antenatal karyotype and the genital appearance; and a family history of DSD, neonatal death or consanguinity.

The salt-wasting CAH crisis is the immediate danger and the assessment is built to catch it. A virilised 46,XX infant with CAH looks like the "safe" end of ambiguity — a girl who is merely virilised — yet she is the one who can collapse. The aldosterone deficiency causes salt wasting that typically declares itself at day 7–14 of life as vomiting, poor feeding, lethargy, weight loss, dehydration and shock, with the biochemical signature of hyponatraemia, hyperkalaemia and metabolic acidosis (and hypoglycaemia from cortisol deficiency). In a setting without universal newborn CAH screening — which is the South African public-sector reality — there is no biochemical safety net, so the crisis is the presentation, and a missed or late diagnosis carries real neonatal mortality. The practical corollary: any sick, dehydrated, hyperkalaemic neonate, and any ambiguous neonate, gets a serum 17-hydroxyprogesterone and an electrolyte panel urgently, and you do not wait for it to be abnormal before treating a shocked baby empirically.

The structured first-line work-up (run in parallel, not in series):

• Karyotype with SRY status (and FISH for X and Y / SRY) — the single most orienting test; a rapid FISH result anchors the differential into the three Chicago groups within a day while the full karyotype follows.
• Electrolytes and 17-hydroxyprogesterone — to find or exclude CAH; 17-OHP is the screening analyte (interpret against gestational/postnatal-age norms, as it is high in the first 48 hours and in preterm infants).
• Adrenal/androgen profile — testosterone, androstenedione, an extended steroid profile (urinary steroid metabolites or serum panel) to localise a biosynthetic block; AMH and inhibin B to confirm functioning testicular tissue.
• Pelvic and adrenal ultrasound — for a uterus (its presence implies absent or failed AMH action, pointing to a 46,XX or a dysgenetic 46,XY) and for gonadal position and adrenal enlargement.
• Where the picture remains unresolved: genitography/examination under anaesthesia to map the urogenital sinus, an hCG stimulation test to probe testosterone synthesis, and increasingly targeted gene panels / exome sequencing, which now establish a molecular diagnosis in a substantial minority that the older biochemical pathway left unexplained.

The older presentation is its own assessment problem. DSD does not only present in the newborn: a phenotypic girl with primary amenorrhoea and a blind vagina but normal breast development and absent/sparse pubic hair is CAIS until proven otherwise (image for absent uterus, karyotype, find the testes); a child with clitoromegaly or progressive virilisation may have non-classic CAH or a virilising tumour; a phenotypic girl who virilises at puberty suggests 5α-reductase deficiency or partial AIS; and an inguinal or labial mass in a "girl" is a gonad until proven otherwise and must not be casually excised. Primary amenorrhoea with short stature and the Turner stigmata (webbed neck, widely spaced nipples, cubitus valgus, coarctation, a horseshoe kidney) points to 45,X gonadal dysgenesis with streak gonads — a sex-chromosome DSD that more often reaches the gynaecologist as delayed puberty than as neonatal ambiguity, and one in which any Y-chromosome material on testing reclassifies the streak gonad as a cancer risk that must come out.

The investigations are interpreted, not just collected. A raised 17-OHP confirms 21-hydroxylase deficiency but is meaningless without age-appropriate norms, and a borderline value in the first 48 hours is repeated rather than acted on. Detectable AMH and inhibin B prove functioning testicular tissue and therefore weigh against a pure gonadal dysgenesis; undetectable AMH in a 46,XY infant points to dysgenetic or absent testes. A flat testosterone response to hCG stimulation in a 46,XY infant localises the block to testosterone synthesis, whereas a normal testosterone with an undervirilised phenotype points to a peripheral problem — androgen-receptor insensitivity (AIS) or, if the testosterone-to-DHT ratio is high, 5α-reductase deficiency. The uterus on ultrasound is the single most discriminating imaging finding, for the reasons set out in the mechanism above.

Management

Order the plan immediate → ongoing → long-term. The immediate work is resuscitation, diagnosis and a held line; the ongoing work is hormone replacement and the staged, consent-respecting decisions about surgery and gonads; the long-term work is fertility, psychological care and transition.

Immediate — keep the baby alive and keep the options open.

• Treat the salt-wasting crisis as an emergency. Resuscitate with intravenous 0.9% sodium chloride for shock and to correct hyponatraemia; treat hyperkalaemia on its merits; correct hypoglycaemia. The specific therapy is parenteral hydrocortisone at stress dose (with its useful mineralocorticoid activity at high dose) the moment CAH is plausible — take the diagnostic bloods first if it costs no time, but never let a confirmatory result delay treating a collapsing baby. Once stable, classic CAH is maintained on oral hydrocortisone (glucocorticoid replacement) plus fludrocortisone (mineralocorticoid), with sodium chloride supplementation in infancy; doses are titrated to growth, 17-OHP/androstenedione and electrolytes, deliberately kept to the minimum that controls androgens, because over-replacement produces iatrogenic Cushing's syndrome and stunts final height.
• Do not assign sex, name the baby, or operate until the multidisciplinary assessment is complete. The honest, non-evasive framing for the parents — "your baby's development is still forming and we need a few days of tests to understand it properly before we can answer your question well" — buys the time that protects the child from a premature, possibly wrong, and socially irreversible commitment.

The multidisciplinary team is the management, not an adjunct to it. No single clinician should make these decisions. The team spans paediatric endocrinology, paediatric urology/surgery, gynaecology, clinical genetics, paediatric/clinical psychology, specialist nursing, social work and clinical ethics, and — increasingly and rightly — trained peer-support/patient representatives. In South Africa this concentrates DSD care at tertiary academic centres; the consultant's job at district and regional level is recognition, the salt-wasting resuscitation, and prompt referral with the karyotype and steroid profile already in motion, not a sex assignment made locally.

Sex of rearing is a probabilistic judgement, made by the team with the parents, not read off the karyotype or the genital appearance. It weighs the specific diagnosis and its known gender-identity outcomes, the prenatal androgen exposure of the brain, the internal anatomy and fertility potential, the surgical options, and the family's social and cultural context. Some conditions carry strong actuarial guidance — a 46,XX CAH infant, however virilised, is genetically female with the potential for fertility and is in the great majority raised female; a CAIS individual is reared female. Others are genuinely uncertain (partial AIS, partial gonadal dysgenesis, 5α-reductase deficiency), and the team's task is to give the most probable answer while being explicit that gender identity in the individual case cannot be predicted with certainty, and that the assignment is a best estimate that the child's own later identity may revise.

The surgery question is the live ethical fault line, and the defensible position is procedural, not a verdict. Two duties have to be reconciled. The first is the established harm of operating early and irreversibly on a child who cannot consent: cosmetic genital surgery in infancy has produced poor sexual and psychological outcomes in a proportion of patients, may not match the gender the person later identifies with, and is increasingly framed as a human-rights issue, with several jurisdictions moving to restrict or ban elective, irreversible genital surgery without the individual's own informed consent. The second is that a minority of interventions are genuinely medically necessary and time-critical — relieving a urogenital-sinus obstruction that impairs urinary drainage, or addressing a functional problem — and these are not the surgery the debate is about. The reconcilable, defensible framework: distinguish the medically necessary from the elective-cosmetic, do the former when indicated, and defer the latter — feminising or masculinising genitoplasty performed for appearance — until the individual is old enough to participate in the decision and give informed assent, with full disclosure to the patient and family throughout. That position does not pretend the dilemma is solved (parents may want early surgery, surgical reversibility is imperfect, and waiting carries its own psychosocial costs); it holds the patient's future autonomy as the tie-breaker and routes the decision through the MDT and a documented consent process rather than through a single surgeon's preference.

Gonadectomy is governed by cancer risk against the value of the gonad, and timing is the variable. Dysgenetic and intra-abdominal Y-bearing gonads carry a raised risk of germ-cell malignancy (gonadoblastoma, which can progress to dysgerminoma/germinoma); the risk depends on the presence of Y-chromosome material (the GBY region) and the degree of gonadal dysgenesis, and is stratified high / intermediate / low by diagnosis. The decisions:

• High-risk gonads — particularly dysgenetic intra-abdominal gonads in 46,XY or 45,X/46,XY mixed gonadal dysgenesis, and the streak gonad of Swyer syndrome — are generally removed; in a streak-gonad, female-reared patient this is often done at diagnosis since the gonad has no endocrine or reproductive value.
• CAIS testes are lower-risk before adulthood and produce useful oestrogen (via aromatisation), so the modern preference is retention with surveillance into adulthood and deferral of gonadectomy, again handing the decision to the informed adult rather than excising in childhood — a deliberate reversal of the older "remove them all early" reflex.
• Where gonads are retained for tumour surveillance, biopsy is best timed to late adolescence, when the histology of germ cells is interpretable (earlier, maturation delay mimics neoplasia and risks over-diagnosis and unnecessary castration).

Long-term care is lifelong and multidimensional. Pubertal induction and maintenance with sex-steroid replacement matched to the sex of rearing; bone-health monitoring (hypogonadism and, in CAH, glucocorticoid exposure both threaten bone); fertility counselling and, where possible, preservation — fertility potential ranges from realistic (well-controlled 46,XX CAH) to absent (gonadal dysgenesis, CAIS), and assisted reproduction or gamete/tissue options must be discussed honestly and early; psychological support as a core, continuous thread, not a referral made only when something goes wrong; transition to adult services, the point at which DSD care most often fails as adolescents disengage; and structured family support including peer networks. The framing throughout is a lifelong condition managed for quality of life, with full disclosure to the growing child appropriate to age.

Some conditions add their own long-term agenda. A Turner-syndrome (45,X) girl needs growth-hormone treatment for short stature, oestrogen for pubertal induction and uterine development, cardiac and renal surveillance, and counselling that spontaneous fertility is rare (oocyte donation is the usual route); if mosaicism reveals Y-chromosome material, gonadectomy of the streak is indicated for tumour risk. A CAH girl raised female needs lifelong glucocorticoid/mineralocorticoid adjustment, an emergency "sick-day" hydrocortisone plan and a medical-alert identifier (the salt-wasting risk does not end in infancy — intercurrent illness, surgery and the peri-partum period all demand stress dosing), attention to fertility (achievable with good control, though a urogenital-sinus anatomy may complicate delivery), and the psychological care that the historical over-virilisation and any genital surgery make essential.

In South Africa the practical constraint is the referral pathway and continuity: definitive DSD care sits at a handful of tertiary academic units with the full MDT, genetics and specialist surgery, while most affected neonates first present at district or regional level. The deliverable plan therefore separates what must happen locally — recognise ambiguity, resuscitate the salt-wasting crisis, take the karyotype/FISH and steroid bloods, hold the line on sex assignment — from what must be referred. The risk to guard against is the adolescent who falls out of follow-up after the neonatal crisis is over; structured transition and a named adult service are part of the long-term plan, not an afterthought.

Guidelines compared

The field is consensus- and ethics-led with few randomised trials, so the "guidelines" are expert-consensus statements that have evolved in a consistent direction — towards holistic multidisciplinary care, conservative deferral of elective surgery, and patient involvement — rather than competing schools.

The substantive divergence is not between bodies but across time and across jurisdictions: the trajectory from the 2006 readiness to operate early towards the 2018/2025 default of deferring elective genital surgery, and the legislative split between countries that now restrict non-consensual childhood genital surgery and those where surgical custom persists. The prenatal dexamethasone question is the other genuine controversy and is dealt with next.

The evidence & the controversy

The central controversy is the timing and legitimacy of irreversible genital surgery in infancy, and it is unusual in medicine for being driven as much by patient advocacy and human-rights argument as by clinical-outcome data. The case against early surgery rests on cohorts reporting suboptimal sexual function, the irreversibility of a decision made for a non-consenting infant, and the real possibility that the surgically reinforced sex will not match the person's later gender identity; the case for it has historically rested on parental distress, presumed psychosocial benefit of "normal-looking" genitalia, and surgical claims of better results when done early. The evidence base is thin on both sides — there are essentially no randomised data, outcome studies are retrospective and confounded by changing techniques, and long-term adult follow-up is exactly the gap the 2018 consensus highlighted. The defensible consultant position is therefore procedural rather than dogmatic: separate the medically necessary from the cosmetic, defer the cosmetic to the individual's own informed assent, and make every such decision through an MDT with documented consent — a stance that respects the autonomy argument without pretending that deferral is cost-free for the family.

Prenatal dexamethasone for CAH is the second live controversy, and the answer is to call it what the guideline calls it: experimental. The rationale is biologically elegant — give a pregnant woman at risk of carrying an affected fetus dexamethasone early enough (before ~9 weeks) to suppress the fetal adrenal and reduce virilisation of an affected 46,XX fetus. The problems are ethical and empirical. Treatment must start before the diagnosis or even the fetal sex is known, so the majority of treated fetuses — all males and unaffected females, roughly seven in eight — are exposed to a potent glucocorticoid for no benefit; and there are unresolved concerns about neurodevelopmental and metabolic effects of early-pregnancy glucocorticoid exposure. The current Endocrine Society guidance is that prenatal dexamethasone should be regarded as experimental and offered only within IRB-approved research protocols with full consent and long-term follow-up — not as routine care. In a South African public-sector setting it is, in practice, not offered.

A quieter but important shift is the rise of molecular diagnosis. Targeted gene panels and exome sequencing now resolve a meaningful share of DSD that the classical karyotype-plus-biochemistry pathway left undiagnosed, which matters clinically because the specific molecular diagnosis informs gender-outcome probabilities, tumour risk and fertility counselling — the precision-medicine direction the 2025 primer endorses. The honest SA framing is access: tertiary genetics and sequencing are available but not uniformly, so the karyotype/FISH-plus-steroid-profile pathway remains the backbone, with molecular testing escalated where it will change management.

Finally, the language and rights debate is itself current and examinable as awareness, not advocacy: the terms "DSD", "differences of sex development", "intersex" and "variations of sex characteristics" are contested between clinicians and parts of the affected community, several countries have legislated against non-consensual infant genital surgery, and the broader societal conversation about sex versus gender bears directly on how these conditions are framed. The consultant holds this with humility — using the patient's and family's preferred terms, disclosing fully, and keeping clinical decisions inside the MDT-and-consent process.

Landmark trials & key evidence

This is a consensus-driven field; the "landmark" documents are the major consensus statements and risk-stratification reviews rather than randomised trials, and they should be cited by name. Effect sizes are largely descriptive (this is not a trial literature), which is itself a point worth making in a viva.

Exam traps & red flags

• Missing salt-wasting CAH. A virilised 46,XX infant reads as the "reassuring" end of ambiguity, yet she is the one who can die of an adrenal crisis at day 7–14. Hyponatraemia + hyperkalaemia + a dehydrated, shocked neonate is salt-wasting CAH until proven otherwise; resuscitate with saline and give stress-dose hydrocortisone — do not wait for the 17-OHP to come back.
• Assigning sex, naming or operating on the labour ward. A premature, irreversible commitment before the MDT work-up is a classic and damaging error; the correct holding line is "we need a few days of tests".
• Excising an inguinal or labial "hernia" in a girl. It may be a testis (CAIS, partial AIS); a gonad is not removed reflexively, and certainly not without a karyotype and a tumour-risk assessment.
• Reading sex of rearing off the karyotype or the genitals alone. It is a probabilistic team judgement weighing diagnosis-specific gender outcomes, prenatal androgenisation, anatomy, fertility and family context — and it is offered as a best estimate, not a certainty.
• Defaulting to early cosmetic genitoplasty. Elective feminising/masculinising surgery for appearance is increasingly deferred to the individual's informed assent; conflating it with the genuinely medically necessary (e.g. obstructive urogenital sinus) is the error — separate the two.
• Removing all gonads early, including CAIS testes. CAIS testes are low-risk before adulthood, produce useful oestrogen, and are now retained with surveillance and deferral; the high-risk dysgenetic/intra-abdominal Y-bearing gonad is the one that comes out.
• Biopsying a retained gonad in early childhood. Maturation delay mimics neoplasia; biopsy is timed to late adolescence to avoid over-diagnosis and unnecessary castration.
• Offering prenatal dexamethasone as routine care. It is experimental and research-protocol-only; treating before sex or affected status is known exposes ~7 in 8 fetuses needlessly.
• Trusting a single biochemical result in the first 48 hours. 17-OHP is physiologically high in the first two days and in preterm infants — interpret against age-appropriate norms.

Evidence anchors

• Consensus statement on management of intersex disorders (Chicago consensus) — Hughes et al., Arch Dis Child 2006
• Global Disorders of Sex Development Update since 2006 — Lee et al., Horm Res Paediatr 2016
• Caring for individuals with a difference of sex development (DSD): a Consensus Statement — Cools et al., Nat Rev Endocrinol 2018
• Differences of sex development — Ahmed, Cools et al., Nat Rev Dis Primers 2025
• Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline — Speiser et al., J Clin Endocrinol Metab 2018
• Germ cell tumors in the intersex gonad — Cools et al., Endocr Rev 2006
• Tumor risk in disorders of sex development (DSD) — Looijenga et al., Best Pract Res Clin Endocrinol Metab 2007
• Germ cell cancer risk in DSD patients — Cools, Ann Endocrinol (Paris) 2014
• South Africa has no universal newborn CAH (17-OHP) screening programme in the public sector, so salt-wasting CAH commonly presents as an electrolyte/adrenal crisis in the first weeks of life rather than via screening; hydrocortisone, fludrocortisone and sodium chloride supplementation for classic CAH are available on the EML/SAMF.